Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
暂无分享,去创建一个
J J Schentag | R N Jones | Jerome J. Schentag | R. Jones | D. Biedenbach | C. Ballow | J. A. Deinhart | D J Biedenbach | C H Ballow | J A Deinhart
[1] R N Jones,et al. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. , 1995, Diagnostic microbiology and infectious disease.
[2] R. Jones,et al. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones , 1996, Antimicrobial agents and chemotherapy.
[3] W J Martone,et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. , 1992, Infection control and hospital epidemiology.
[4] J. Duval,et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus , 1995, Antimicrobial agents and chemotherapy.
[5] G. Doern,et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study , 1996, Antimicrobial agents and chemotherapy.
[6] G. Montay,et al. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. , 1997, The Journal of antimicrobial chemotherapy.
[7] Jerome J. Schentag,et al. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. , 1997, Diagnostic microbiology and infectious disease.
[8] R. Jones,et al. Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest. , 1996, The Journal of antimicrobial chemotherapy.
[9] M. Arthur,et al. Mechanisms of glycopeptide resistance in enterococci. , 1996, The Journal of infection.
[10] M. Levison,et al. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. , 1995, Diagnostic microbiology and infectious disease.
[11] G. Eliopoulos,et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms , 1993, Antimicrobial Agents and Chemotherapy.
[12] D. Landman,et al. Management of infections due to resistant enterococci: a review of therapeutic options. , 1997, The Journal of antimicrobial chemotherapy.
[13] P. Gilligan,et al. Emergence of vancomycin resistance in coagulase-negative staphylococci. , 1987, The New England journal of medicine.
[14] M. Zervos,et al. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. , 1996, Diagnostic microbiology and infectious disease.
[15] B. Doebbeling,et al. The worldwide prevalence of methicillin-resistant Staphylococcus aureus. , 1995, International journal of antimicrobial agents.
[16] P. Brennan,et al. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Ronald N. Jones,et al. Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum. , 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] A. Barry,et al. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. , 1997, The Journal of antimicrobial chemotherapy.
[19] J. Verhaegen,et al. Comparative in-vitro activity of RP 59500. , 1992, The Journal of antimicrobial chemotherapy.
[20] N Woodford,et al. Current perspectives on glycopeptide resistance , 1995, Clinical microbiology reviews.
[21] R. Jones,et al. Evaluation of Vitek and API 20S for species identification of enterococci. , 1995, Diagnostic microbiology and infectious disease.
[22] C. Stratton,et al. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. , 1993, Diagnostic microbiology and infectious disease.
[23] E. Rubinstein,et al. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. , 1997, The Journal of antimicrobial chemotherapy.
[24] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.
[25] R. Quintiliani,et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. , 1995, Diagnostic microbiology and infectious disease.
[26] R. Fass. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci , 1991, Antimicrobial Agents and Chemotherapy.
[27] G. Eliopoulos,et al. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium , 1997, Antimicrobial agents and chemotherapy.
[28] S. Miyazaki,et al. The in-vitro activity of RP 59500 against gram-positive cocci. , 1992, The Journal of antimicrobial chemotherapy.
[29] R. Wenzel,et al. Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital. , 1993, Journal of chemotherapy.
[30] W. Noble,et al. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.
[31] J. Pechère. Streptogramins. A unique class of antibiotics. , 1996, Drugs.
[32] R. Wenzel,et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. , 1997, Diagnostic microbiology and infectious disease.
[33] M. Zervos,et al. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] J. Silber,et al. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci , 1997, Antimicrobial agents and chemotherapy.
[35] F. Tenover,et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.
[36] R. Moellering. The enterococcus—A versatile pathogen , 1997 .
[37] R. Jones,et al. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing. , 1997, Diagnostic microbiology and infectious disease.
[38] J. Duval,et al. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145 , 1993, Antimicrobial Agents and Chemotherapy.
[39] J. Fung,et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.